Evidence map›Paper›PMID 31735500›Full record

Trial reportVaccine2020

A phase I trial evaluating the safety and immunogenicity of a candidate tuberculosis vaccination regimen, ChAdOx1 85A prime - MVA85A boost in healthy UK adults.

Morven Wilkie, Iman Satti, Alice Minhinnick, Stephanie Harris, Michael Riste, Raquel Lopez Ramon, Sharon Sheehan, Zita-Rose Manjaly Thomas, Daniel Wright, Lisa Stockdale and 10 more

Open access · hybridAbstract readClinical Trial, Phase IRandomized Controlled Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Vaccine, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 61 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
61citing papers in PubMed, 1 pooled it
6.4field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

61 citing papers in PubMed, 1 synthesis or guideline pooled it, 89 citations in OpenAlex.

  1. Pooled it
  2. Trial
  3. Trial
  4. Trial
  5. Antigen 85B ofVaccines · 2026
    Review
  6. Article
  7. Article
  8. HowVaccines · 2026
    Review
  9. Review
  10. Review
  11. RNA vaccines: The dawn of a new age for tuberculosis?Human vaccines & immunotherapeutics · 2025
    Review
  12. Article
  13. Article
  14. Review
  15. Review
  16. Review
  17. Article
  18. Host Immune Response toJournal of inflammation research · 2025
    Review
  19. Review
  20. Review

1 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

20 authors at 2 institutions in 1 country.

Morven WilkieThe Jenner Institute, University of Oxford, Oxford OX3 7DQ, UK.
Iman SattiThe Jenner Institute, University of Oxford, Oxford OX3 7DQ, UK.
Alice MinhinnickThe Jenner Institute, University of Oxford, Oxford OX3 7DQ, UK.
Stephanie HarrisThe Jenner Institute, University of Oxford, Oxford OX3 7DQ, UK.
Michael RisteThe Jenner Institute, University of Oxford, Oxford OX3 7DQ, UK.
Raquel Lopez RamonThe Jenner Institute, University of Oxford, Oxford OX3 7DQ, UK.
Sharon SheehanThe Jenner Institute, University of Oxford, Oxford OX3 7DQ, UK.
Zita-Rose Manjaly ThomasThe Jenner Institute, University of Oxford, Oxford OX3 7DQ, UK.
Daniel WrightThe Jenner Institute, University of Oxford, Oxford OX3 7DQ, UK.
Lisa StockdaleThe Jenner Institute, University of Oxford, Oxford OX3 7DQ, UK.
Ali HamidiThe Jenner Institute, University of Oxford, Oxford OX3 7DQ, UK.
Matthew K O'SheaThe Jenner Institute, University of Oxford, Oxford OX3 7DQ, UK.
Kritica DwivediThe Jenner Institute, University of Oxford, Oxford OX3 7DQ, UK.
Hannah Michaela BehrensThe Jenner Institute, University of Oxford, Oxford OX3 7DQ, UK.
Tamara DavenneThe Jenner Institute, University of Oxford, Oxford OX3 7DQ, UK.
Joshua MortonThe Jenner Institute, University of Oxford, Oxford OX3 7DQ, UK.
Samantha VermaakThe Jenner Institute, University of Oxford, Oxford OX3 7DQ, UK.
Alison LawrieThe Jenner Institute, University of Oxford, Oxford OX3 7DQ, UK.
Paul MossInstitute of Immunology and Immunotherapy, University of Birmingham, Edgbaston, Birmingham B15 2TT, UK.
Helen McShaneThe Jenner Institute, University of Oxford, Oxford OX3 7DQ, UK. Electronic address: helen.mcshane@ndm.ox.ac.uk.
University of Oxford · GBUniversity of Birmingham · GB

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundThis phase I trial evaluated the safety and immunogenicity of a candidate tuberculosis vaccination regimen, ChAdOx1 85A prime-MVA85A boost, previously demonstrated to be protective in animal studies, in healthy UK adults.

methodsWe enrolled 42 healthy, BCG-vaccinated adults into 4 groups: low dose Starter Group (n = 6; ChAdOx1 85A alone), high dose groups; Group A (n = 12; ChAdOx1 85A), Group B (n = 12; ChAdOx1 85A prime - MVA85A boost) or Group C (n = 12; ChAdOx1 85A - ChAdOx1 85A prime - MVA85A boost). Safety was determined by collection of solicited and unsolicited vaccine-related adverse events (AEs). Immunogenicity was measured by antigen-specific ex-vivo IFN-γ ELISpot, IgG serum ELISA, and antigen-specific intracellular IFN-γ, TNF-α, IL-2 and IL-17.

resultsAEs were mostly mild/moderate, with no Serious Adverse Events. ChAdOx1 85A induced Ag85A-specific ELISpot and intracellular cytokine CD4+ and CD8+ T cell responses, which were not boosted by a second dose, but were boosted with MVA85A. Polyfunctional CD4+ T cells (IFN-γ, TNF-α and IL-2) and IFN-γ+, TNF-α+ CD8+ T cells were induced by ChAdOx1 85A and boosted by MVA85A. ChAdOx1 85A induced serum Ag85A IgG responses which were boosted by MVA85A.

conclusionA ChAdOx1 85A prime - MVA85A boost is well tolerated and immunogenic in healthy UK adults.

Indexed as

AdultBCG VaccineCD4-Positive T-LymphocytesCD8-Positive T-LymphocytesCytokinesFollow-Up StudiesHumansImmunization, SecondaryImmunogenicity, VaccineTuberculosisTuberculosis VaccinesUnited KingdomVaccinationVaccines, DNABCG VaccineCytokinesMVA 85ATuberculosis VaccinesVaccines, DNAChAdOx1 85AImmunogenicityMVA85ASafetyTuberculosisVaccine

Identifiers

PMID31735500
PMCPMC6985898
OpenAlexW2989005130

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.